MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
common stock and...
$100,002K
Proceeds from sale of
business, net cash, cash...
$101,286K
Proceeds from issuance
under employee stock...
$49K
Issuance of common stock
upon exercise of...
$26K
Maturities of short-term
investments
$59,845K
Net cash provided by
financing activities
$94,376K
Net cash provided by
investing activities
$11,891K
Canceled cashflow
$5,701K
Canceled cashflow
$149,240K
Net increase
(decrease) in cash, cash...
$8,834K
Canceled cashflow
$97,433K
Payment of pipe
financing related...
$5,625K
Deferred offering costs
paid for financing
$76K
Share-based compensation
expense
$9,873K
Accounts payable and
accrued liabilities
$3,923K
Inventory
-$170K
Depreciation and
amortization expense
$79K
Non-cash lease expense
$74K
Purchases of short-term
investments
$148,688K
Purchases of property and
equipment
$552K
Net cash used in
operating activities
-$97,433K
Canceled cashflow
$14,119K
Gain on sale of
business
$87,266K
Net loss
-$20,596K
Amortization of premiums and
discounts on short-term...
$1,527K
Accounts receivable
$1,000K
Other non-current
assets
$438K
Prepaid expenses and
other current assets
$434K
Other liabilities
-$202K
Operating lease
liabilities, net
-$89K
Back
Back
Cash Flow
source: myfinsight.com
Whitehawk Therapeutics, Inc. (WHWK)
Whitehawk Therapeutics, Inc. (WHWK)